Serum TIMP-1 shows a potential association with metastatic disease in patients with pancreatic cancer: a pilot analysis without a healthy control cohort
Ivana Vecurkovska, Veronika Roskovicova, Tomas Gajdzik, Marek Soltes, Jana Maslankova, Ivana Kocanova, Jana Katuchova · 2026
Read Serum TIMP-1 shows a potential association with metastatic disease in patients with pancreatic cancer: a pilot analysis without a healthy control cohort by Ivana Vecurkovska, Veronika Roskovicova, Tomas Gajdzik, Marek Soltes, Jana Maslankova, Ivana Kocanova, Jana Katuchova (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13574921.txt.
Description
Ivana Vecurkovska leads a 2026 pilot study on a blood protein in pancreatic cancer. The protein, TIMP-1, has links to tumour spread, yet its value in this cancer was not well defined. Pancreatic cancer is most often found late, after spread has already occurred and cure is unlikely.
The team measured TIMP-1 in blood and tissue from 154 patients, 108 with malignant tumours and 46 with benign growths. Levels ran higher in cancer, and blood levels ran higher still in patients whose disease had spread to distant sites. Blood testing separated groups somewhat better than tissue testing. The authors stress the gaps were modest, so TIMP-1 suits combined marker panels rather than use on its own.
Catalog record
| CREATOR | Ivana Vecurkovska, Veronika Roskovicova, Tomas Gajdzik, Marek Soltes, Jana Maslankova, Ivana Kocanova, Jana Katuchova |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34273 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |